Patient registry for people treated with oNKord®
Part of Blood & lymphatic, Cancer clinical trials.
This trial is a registry that collects information from people who received at least one dose of oNKord® in a clinical study. It may help researchers better understand what happens after treatment and support future research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received at least one dose of oNKord® in a clinical trial.
- You must be joining within 3 years after your first oNKord® infusion.
- You must be able to sign the consent form (ICF).
- There are no listed exclusion criteria for this registry.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial tests a new drug, FD-001, for people with certain blood cancers (like leukemia, lymphoma, or myeloma) that have come back or stopped responding to standard treatments. The goal is to see if the drug is safe and how well it might work.
This study collects samples and health information from people with certain blood cancers to learn more about the disease and find markers that may help guide future treatments. You will not receive a treatment from this study, but you may help advance research.
This trial is a “patient registry,” which collects health information over time to help researchers plan and run future studies. It may help by contributing your experience so new treatments can be tested more effectively.
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
This is a registry study that collects information from people with myeloid blood diseases. It helps researchers better understand these conditions and support future research.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.